证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-055 贤丰控股股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 贤丰控股股份有限公司（以下简称"公司"、"上市公司"或"贤丰控股"） 于 2025 年 5 月 12 日收到深圳证券交易所上市公司管理二部发出的《关于对贤丰 控股股份有限公司 2024 年年报的问询函》（公司部年报问询函〔2025〕第 120 号），经过认真自查并与相关机构充分沟通后，公司、深圳广深会计师事务所（普 通合伙）(以下简称"深圳广深"、"年审会计师" 或"我们")对有关问题进 行了书面回复。现将回复内容公告如下（下文简称与 2024 年年度报告一致）： 扣除后营业收入 4.18 亿元；实现归属于上市公司股东的净利润-1.13 亿元，公 司已连续两年大额亏损。你公司前三季度营业收入仅为 0.46 亿元，第四季度公 司开展覆铜板业务实现营业收入 3.14 亿元。请你公司： （1）说明导致公司持续亏损的因素是否仍然存在并具有持续性，持续亏损 的状态未来能否得到扭转或消除，你公司已经采取的应对措施，并请结合主营业 ...

Core Viewpoint - Reap Bio plans to divest 48.4213% of its stake in Zhong'an Bio due to the latter's failure to achieve expected returns from a fundraising project and the company's shift towards the pet business [1][2][3] Group 1: Divestment Details - Reap Bio will transfer its controlling stake in Zhong'an Bio to Jiangxi Twin Biological Technology Co., with the transaction price set at 115 million yuan, reflecting a 15.3% premium on the overall valuation of 237 million yuan [2][3] - Zhong'an Bio, established in 2010, primarily produces livestock vaccines, with an annual production capacity of approximately 300 million doses [2] Group 2: Financial Performance - In 2024, Zhong'an Bio reported a revenue of 48.98 million yuan, down nearly 12% year-on-year, and incurred a loss of 459,600 yuan [3][8] - The net asset value of Zhong'an Bio was reported at 206 million yuan as of 2024 [2] Group 3: Strategic Shift - Reap Bio's divestment is part of a broader strategy to focus on its core business and mitigate losses from underperforming assets [3][6] - The company has been actively acquiring stakes in the pet industry, including a 15% stake in Zhongrui Huapu Technology for 131 million yuan, indicating a strategic pivot towards the pet supply chain [4][7] Group 4: Financial Risks - Reap Bio's short-term interest-bearing liabilities reached 862 million yuan in 2024, a 55% increase year-on-year, while long-term loans rose by 67% to 514 million yuan [5] - The company's asset-liability ratio increased from 27% to 37%, indicating growing financial leverage [5] Group 5: Profitability Challenges - In 2024, Reap Bio's net profit declined by 33.7%, attributed to rising raw material costs, increased R&D and financial expenses, and a significant drop in non-recurring gains [8] - The overall gross margin fell from 49.69% in 2023 to 41.38% in 2024, reflecting pressure on profitability [8] Group 6: Operational Concerns - Accounts receivable rose to 1.07 billion yuan, and inventory increased from 390 million yuan to nearly 500 million yuan, indicating potential liquidity issues [9] - The company's ability to successfully integrate and grow its pet business will be critical for its long-term performance amid current challenges [9]

股票代码：002141 股票简称：*ST 贤丰 贤丰控股股份有限公司投资者关系活动记录表 编号：2025-001 | 投资者关系活 | □特定对象调研 □分析师会议 | | --- | --- | | 动类别 | □媒体采访 ☑业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 （） | | 参与单位名称 | 线上参与贤丰控股 2024 年度网上业绩说明会的投资者 | | 及人员姓名 | | | 时间 | 2025 年 04 月 30 日（星期三）15:00-17:00 | | 地点 | "约调研"小程序 | | 上市公司接待 | 董事长：韩桃子女士 | | 人员姓名 | 董事、总经理：丁晨先生 | | | 独立董事：肖世练、邓延昌、梁融 | | | 董事会秘书、副总经理：梁丹妮女士 | | | 董事、财务总监：谢文彬先生 | | | 公司于 2025 年 4 月 30 日 15:00-17:00 在"约调研"小程序 | | | 举行 2024 年度业绩说明会。本次业绩说明会采用网络远程的 | | | 方式举行，公司与会高管在问答环节对投资者提出的共计 18 | | | 条问题均 ...